Recent reviews have emphasized the need for a health equity agenda in genomics
research. To ensure that genomic discoveries can lead to improved health outcomes for all …

Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Importance Monogenic familial hypercholesterolemia (FH) is associated with lifelong
elevations in low-density lipoprotein cholesterol (LDL-C) levels and increased risk of …

A key factor to successful secondary prevention of cardiovascular disease (CVD) is optimal
patient adherence to treatment. However, unsatisfactory rates of adherence to treatment for …

Despite the availability of effective therapies that lower low‐density lipoprotein cholesterol
(LDL‐C) levels in patients with atherosclerotic cardiovascular disease, many eligible …

Abstract Purpose of Review To highlight the gender-based differences in presentation and
disparities in care for women with familial hypercholesterolemia (FH). Recent Findings …

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United
States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for …

Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated
low-density lipoprotein (LDL)-cholesterol (LDL-C) levels and early onset of atherosclerotic …

Background and aims Despite lipid lowering therapy (LLT), reaching LDL-C targets in
patients with familial hypercholesterolemia (FH) remains challenging. Our aim was to …

Utilization management strategies, including prior authorization, are commonly used to
facilitate safe and guideline-adherent provision of new, individualized, and potentially costly …